Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 16:10 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026$151.3 million in cash, cash equivalents, and short-term...
May 07, 2025 16:05 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...
March 31, 2025 16:10 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a...
February 12, 2025 22:38 ET | Source: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Pricing of Initial Public Offering

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule...